biostudies-literatureFang JMajor National Science and Technology Projects, ChinaShanghai Cell Therapy Group Corporatione001162https://www.ebi.ac.uk/biostudies/studies/S-EPMC7887368biostudies-literatureUnknown9(2)Epithelial ovarian cancer (EOC) is the leading cause of death among gynecological malignancies in China. In particular, advanced/refractory ovarian cancer lacks effective targeted therapies due to the immunosuppressive and proangiogenic tumor microenvironment. Mesothelin (MSLN) has been found to be highly expressive in most EOC. Targeting MSLN by antibodies or chimeric antigen receptor-modified T (CAR-T) cells and immune checkpoint blockades as well as apatinib, an anti-angiogenic drug, have been used in patients with refractory ovarian cancer. Apatinib was reported to promote the infiltration of CD8⁺ T cells in lung cancer. However, the combination therapy of CAR-T secreting anti-PD-1 antibody with apatinib in EOC has not been reported.<h4>Case presentation</h4>Here we report aJournal for immunotherapy of cancerαPD-1-mesoCAR-T cells partially inhibit the growth of advanced/refractory ovarian cancer in a patient along with daily apatinib.PMC78873682018ZX10302207-003; 2019YFC1316202BZ1903Fang JGuo XChu WXu QDing NWang HLin ZYuan MSun YLi ZZhang ZMao WQin HQin FQian QXie BfalseαPD-1-mesoCAR-T cells partially inhibit the growth of advanced/refractory ovarian cancer in a patient along with daily apatinib.Epithelial ovarian cancer (EOC) is the leading cause of death among gynecological malignancies in China. In particular, advanced/refractory ovarian cancer lacks effective targeted therapies due to the immunosuppressive and proangiogenic tumor microenvironment. Mesothelin (MSLN) has been found to be highly expressive in most EOC. Targeting MSLN by antibodies or chimeric antigen receptor-modified T (CAR-T) cells and immune checkpoint blockades as well as apatinib, an anti-angiogenic drug, have been used in patients with refractory ovarian cancer. Apatinib was reported to promote the infiltration of CD8⁺ T cells in lung cancer. However, the combination therapy of CAR-T secreting anti-PD-1 antibody with apatinib in EOC has not been reported.<h4>Case presentation</h4>Here we report a2021-01-01T00:00:00Z2021 Feb2026-06-14T07:47:35.243Z2024-11-15T19:16:44.528ZS-EPMC78873683358952010.1136/jitc-2020-001162